Dr. April Erwin, The NeuroMedical Center Enroll World’s First Patient in Phase III MS Clinical Trial

July 20, 2020 1:30 pm

MS Neurologist to serve as lead investigator in major study for relapsing multiple sclerosis

The NeuroMedical Center is excited to announce that MS neurologist, Dr. April A. Erwin, in partnership with Delricht Research, has enrolled the world’s first patient in a Phase III clinical trial to test the safety and effectiveness of an investigational, brain-penetrant, oral therapy to treat patients with relapsing multiple sclerosis (MS). The investigational drug SAR442168, being developed by Sanofi, a global biopharmaceutical company, aims to be the first disease-modifying therapy for MS with a mechanism of action related to Bruton’s Tyrosine Kinase inhibition. Dr. Erwin will serve as a principal investigator in this clinical trial, which will be conducted in 40 countries around the world.

MS is a chronic, neurodegenerative autoimmune disease that results in inflammation of the protective covering around nerves in the brain and spinal cord, which may result in debilitating neurologic symptoms. There is no cure for MS, and currently FDA-approved therapies aim to prevent MS relapses, MRI lesions, and clinical disability. According to Dr. Erwin, “Innovative studies like the SAR442168 clinical trial sponsored by Sanofi are important to help determine whether this investigational drug could be beneficial for patients with relapsing MS.”

Enrollment is now open for the SAR442168 Clinical Trial at The NeuroMedical Center and at test sites worldwide. Researchers will enroll 900 patients in this global, randomized, double-blind efficacy and safety trial. For more information on how to enroll for this clinical trial or to learn more about The NeuroMedical Center’s Clinical Research department click here.

Categorised in: Clinic News, NMC News